Skip to main content

Table 1 Association between HES9 expression and clinicopathological parameters

From: Podocalyxin is a marker of poor prognosis in colorectal cancer

HES9 expression
  Low High  
n (%) 723 (94.3) 44 (5.7) p-value
Age, years    
<65 309 (42.7) 16 (36.4) 0.436
≥65 414 (57.3) 28 (63.6)  
Gender    
Male 402 (44.4) 24 (54.5) 1.000
Female 321 (55.6) 20 (45.5)  
Dukes    
A 109 (15.1) 2 (4.5) 0.012
B 259 (35.8) 13 (29.5)  
C 196 (27.1) 14 (31.8)  
D 159 (22.0) 15 (34.1)  
Grade (WHO)    
1 26 (3.6) 0 (0) <0.0001
2 514 (71.5) 11 (25.0)  
3 161 (22.4) 25 (56.8)  
4 18 (2.5) 8 (18.2)  
Missing 4   
Location    
Colon 372 (51.5) 28 (63.6) 0.123
Rectum 351 (48.5) 16 (36.3)  
Side    
Right 189 (26.1) 23 (52.3) <0.001
Left 534 (73.9) 21 (47.7)  
  1. Fisher exact-test for 2 × 2 tables and linear-by-linear association test for tables with more than two rows. Missing data excluded from analyses. MAb HES9 recognises PODXL protein.
\